Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCTox: Hydrochlorothiazide and Dermal Photosensitivity
NCT04654312Phase 1Completed
- Sponsor
- Saarland University
- Start
- Jan 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Saarland University. Primary endpoints: Minimal Erythema Dose at 2 weeks and Excretion of Pyrimidine Dimers at 26 days. Started Jan 2021; status: completed.
02
Drugs
hydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04654312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04654312.